Stem definition | Drug id | CAS RN |
---|---|---|
analgesics, pethidine derivatives and other synthetic small molecule miu-opioid receptor agonists | 5406 | 1401028-24-7 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 7, 2020 | FDA | TREVENA INC |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | N02AX07 | NERVOUS SYSTEM ANALGESICS OPIOIDS Other opioids |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Moderate pain | indication | 50415004 | |
Severe pain | indication | 76948002 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Decreased respiratory function | contraindication | 80954004 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Asthma | contraindication | 195967001 | DOID:2841 |
None
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
1MG/ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 11077098 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
1MG/ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 8835488 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
1MG/ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 9309234 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
1MG/ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 9642842 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
2MG/2ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 11077098 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
2MG/2ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 8835488 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
2MG/2ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 9309234 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
2MG/2ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 9642842 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
30MG/30ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 11077098 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
30MG/30ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 8835488 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
30MG/30ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 9309234 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
30MG/30ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | 9642842 | March 23, 2032 | MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1MG/ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | Oct. 30, 2025 | NEW CHEMICAL ENTITY |
2MG/2ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | Oct. 30, 2025 | NEW CHEMICAL ENTITY |
30MG/30ML (1MG/ML) | OLINVYK | TREVENA | N210730 | Oct. 30, 2020 | RX | SOLUTION | INTRAVENOUS | Oct. 30, 2025 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mu-type opioid receptor | GPCR | AGONIST | Ki | 8.22 | DRUG LABEL | DRUG LABEL | |||
Sodium channel protein type 5 subunit alpha | Ion channel | IC50 | 5.33 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.21 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 4.44 | CHEMBL | |||||
Nociceptin receptor | GPCR | AGONIST | EC50 | 7.40 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
D11214 | KEGG_DRUG |
MCN858TCP0 | UNII |
C4508938 | UMLSCUI |
WH2 | PDB_CHEM_ID |
CHEMBL2443262 | ChEMBL_ID |
66553195 | PUBCHEM_CID |
DB14881 | DRUGBANK_ID |
7334 | IUPHAR_LIGAND_ID |
018475 | NDDF |
897038008 | SNOMEDCT_US |
897041004 | SNOMEDCT_US |
4039828 | VANDF |
2392230 | RXNORM |
341480 | MMSL |
d09691 | MMSL |
C586842 | MESH_SUPPLEMENTAL_RECORD_UI |
10250 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
OLINVYK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71308-011 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | NDA | 31 sections |
OLINVYK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71308-011 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | NDA | 31 sections |
OLINVYK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71308-021 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | NDA | 31 sections |
OLINVYK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71308-021 | INJECTION, SOLUTION | 2 mg | INTRAVENOUS | NDA | 31 sections |
OLINVYK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71308-301 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | NDA | 31 sections |
OLINVYK | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71308-301 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | NDA | 31 sections |